

## Press Release

### Cellzome further builds out preclinical capability with industry experienced hires

**Cambridge, UK, 1<sup>st</sup> December 2010** – Cellzome announced today the hire of Dr. Tammy Ladduwahetty and Dr. Steven Etheridge to strengthen its preclinical capabilities.

The hires follow the appointment of Dr. Alan Watt as head of the Therapeutics division of Cellzome earlier this year.

Dr. Tammy Ladduwahetty brings more than 20 years of experience in Medicinal Chemistry to Cellzome. She started her career with a PhD from the University of Pennsylvania, followed by a postdoctoral fellowship at the University of Cambridge, UK. She then spent 19 years at Merck Sharp & Dohme where she was in her last position promoted to Senior Research Fellow and contributed with her group to the delivery of clinical candidates for various projects. Tammy joined Biofocus in 2006, where she was most recently leading a team of scientists, responsible for library design.

Dr Steven Etheridge was, in his previous position before joining Cellzome, Associate Project Director at Novartis. He is a trained toxicologist and worked for more than 15 years at GlaxoSmithKline (GSK) in toxicology, before spending two years as Principle Regulatory Manager and finally a further four years as Drug Development Manager. During his time at GSK, Steven was sponsored to obtain a degree in pharmacology and a PhD in toxicology with the University of Leicester. After GSK, he gained additional experience in the biotech sector, working in preclinical project management.

Dr. Alan Watt, VP Therapeutics at Cellzome said: “Tammy and Steve are great additions to our Therapeutics team; both come with an exceptional track record and their skill set is rounding out Cellzome’s preclinical capabilities. I am looking forward, with our team, to deliver a stream of innovative new development candidates for us and our partners.”

- ends -

**For more information please contact:**

**Cellzome:**

Dr. Alan Watt  
Vice President Therapeutics  
Tel: +49 (0) 6221-137 57-100  
press@cellzome.com

**Media contact:**

MHP Communications  
John Olsen  
Tel: +44 (0) 207 357 9477

## About Cellzome

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases.

Our pipeline of small-molecule therapeutics is driven by *Kinobeads*<sup>™</sup>, a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called *Episphere*<sup>™</sup> to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Cellzome has two strategic alliances with GSK to discover and develop drugs to treat inflammatory diseases, the first in the field of kinase-targeted therapeutics and the second in the field of epigenetics.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two R&D laboratories in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: [www.cellzome.com](http://www.cellzome.com)